drugset / Trial / NCT00215800
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
RandomizedParallel-groupDouble-blindTreatment
Summary
multi-center, double-blind, randomized, placebo-controlled study of the safety and efficacy.
Timeline
- Start
- 1998-12
- Primary completion
- 2004-02
- Completion
- 2004-02
Publications
- Strayer DR, Young D, Mitchell WM. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS One. 2020 Oct 29;15(10):e0240403. doi: 10.1371/journal.pone.0240403. eCollection 2020.
- Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell WM. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334. doi: 10.1371/journal.pone.0031334. Epub 2012 Mar 14.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rintatolimod | Oligonucleotide (other) | 400 mg | Intravenous |